Condition (MeSH)
Hypoalphalipoproteinemias
ClinicalTrials.gov lists 80 trials for Hypoalphalipoproteinemias or a narrower condition beneath it. IPCA Laboratories Ltd. has the most among industry and government lead sponsors, with 12.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
14 of the 80 trials are tagged with Hypoalphalipoproteinemias itself; the rest are tagged with a narrower condition beneath it.
When did Hypoalphalipoproteinemias trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 15
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2024 | 2 |
| 2023 | 4 |
| 2022 | 3 |
| 2019 | 4 |
| 2018 | 3 |
| 2017 | 3 |
| 2016 | 1 |
| 2015 | 1 |
Showing 10 of 25 earlier years.
No forecast is made for this condition: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hypoalphalipoproteinemias trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 1 |
| Phase 3 | 5 |
| Phase 4 | 3 |
| Not applicable | 12 |
| Observational | 7 |
How many Hypoalphalipoproteinemias trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 3 |
| Completed | 69 |
| Terminated | 3 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hypoalphalipoproteinemias trials? (10)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| IPCA Laboratories Ltd. | 12 |
| Par Pharmaceutical, Inc. | 11 |
| Dr. Reddy's Laboratories Limited | 7 |
| Pfizer | 4 |
| National Heart, Lung, and Blood Institute (NHLBI) | 3 |
Showing 5 of 10 sponsors.
Which drugs are being tested for Hypoalphalipoproteinemias? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| ROSUVASTATIN | 2 |
| Lisinopril | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| PO Morphine | 2 |
| IM olanzapine | 2 |
| Ultracet | 2 |
| 1% Metformin | 2 |
| Ondansetron - Parts A + B | 2 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hypoalphalipoproteinemias trials report? (7)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Liver-related death | 24 | 1 |
| Anaphylactic Reaction | 1 | 1 |
| Angina Unstable | 1 | 1 |
| Complication Associated with Device | 1 | 1 |
| Non-liver-related death | 1 | 1 |
Showing 5 of 7 adverse events.
Which publications cover Hypoalphalipoproteinemias? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The ATP-binding cassette transporter A1 R230C variant affects HDL cholesterol levels and BMI in the Mexican population: association with obesity and obesity-related comorbidities. | Diabetes | 2007 | Yes |
| NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial. | Atherosclerosis | 2019 | No |
| Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy. | Atherosclerosis | 2013 | No |
| Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). | Journal of the American College of Cardiology | 2013 | No |
| Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006. | Salud publica de Mexico | 2010 | No |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Hypoalphalipoproteinemia | 31153 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Hypoalphalipoproteinemia | 31153 | Exact | Orphadata Science knowledge files, Product 1 |
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence.